• 1
    White SD, Rosser EJ, Ihrke PJ, Stannard AA. Bullous pemphi-goid in a dog: Treatment with six-mercaptopurine. J Am Vet Med Assoc 1984;185:683686.
  • 2
    Willard MD. Inflammatory bowel disease: Perspectives on therapy. J Am Anim Hosp Assoc 1992;28:2732.
  • 3
    Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of aza-thioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193197.
  • 4
    Cuffari C., Theoret Y., Latour S., Seidman G. 6-Mercaptopuine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 1996;39:401406.
  • 5
    Rinkardt NE, Kruth SA. Azathioprine-induced bone marrow tox-icity in four dogs. Can Vet J 1996;37:612613.
  • 6
    Lennard L., Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41:1825.
  • 7
    Chan GLC, Erdmann GR, Gruber SA, et al. Azathioprine metabolism: Pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990;30:358363.
  • 8
    Sebbag L., Boucher P., Davelu P., et al. Thiopurine S-methyltrans-ferase gene polymorphism is predictive of azathioprine-induced mye-losuppression in heart transplant recipients. Transplantation 2000;69:15241527.
  • 9
    Elion GB. Biochemistry and pharmacology of purine analogues. Fed Proc 1967;26:898904.
  • 10
    Rees AJ, Lockwood CM. Immunosuppressive drugs in clinical practice. In: LachmanPJ, PetersDK, eds. Clinical Aspects of Immunology, 4th ed. London : Blackwell; 1982: 507564.
  • 11
    Ogilvie GK, Felsburg PJ, Harris CW. Short-term effect of cy-clophosphamide and azathioprine on selected aspects of the canine blastogenic response. Vet Immunol Immunopathol 1988; 18: 119127.
  • 12
    Stolk JN, Boerbooms AMT, de Abreu RA, et al. Reduced thio-purine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:18581866.
  • 13
    Beale KM. Azathioprine for treatment of immune-mediated diseases of dogs and cats. J Am Vet Med Assoc 1988;192:13161318.
  • 14
    Houston DM, Taylor JA. Acute pancreatitis and bone marrow suppression in a dog given azathioprine. Can Vet J 1991;32:496497.
  • 15
    Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001;7:181189.
  • 16
    Lennard L. Clinical implications of thiopurine methyltransfer-ase–Optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998;20:527531.
  • 17
    Otterness DM, Keith RA, Weinshilboum RM. Thiopurine meth-yltransferase: Mouse kidney and liver assay conditions, biochemical properties and strain variation. Biochem Pharmacol 1985;34:38233830.
  • 18
    Weinshilboum RM, Raymond FA, Pamzino PA. Human eryth-rocyte thiopurine methyltransferase: Radiochemical micro assay and biochemical properties. Clin Chim Acta 1978;85:323333.
  • 19
    Woodson LC, Dunnette JH, Weinshilboum RM. Pharmacoge-netics of human thiopurine methyltransferase: Kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 1982;22:174181.
  • 20
    Szumlanski CL, Hinchel R., Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics–Biochem-ical properties, liver-erythrocyte correlation and presence of isoen-zymes. Pharmacogenetics 1992;2:148159.
  • 21
    Lennard L., Lilleyman JS. Individualizing therapy with 6-mer-captopurine and 6-thioguanine related to the thiopurine methyltrans-ferase genetic polymorphism. Ther Drug Monit 1996;18:328334.
  • 22
    Ansari A., Hassan C., Duley J., et al. Thiopurine methyltransfer-ase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:17431750.
  • 23
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacoge-netics: Monogenic inheritance of erythrocyte thiopurine methyltrans-ferase activity. Am J Hum Genet 1980;32:651662.
  • 24
    Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyl-transferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in caucasians. Am J Hum Genet 1996;58:694702.
  • 25
    McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14:567572.
  • 26
    Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyl-transferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716718.
  • 27
    Andersen JB, Szumlanski C., Weinshilboum RM, Schmiegelow K. Pharmacokinetics, dose adjustments and 6-mercaptopuine/metho-trexate drug interactions in two patients with thiopurine methyltrans-ferase deficiency. Acta Paediatr 1998;87:108111.
  • 28
    Krynetski E., Schuetz JD, Galpin AJ, et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-meth-yltransferase. Proc Natl Acad Sci U S A 1995;92:949953.
  • 29
    Tavadia SMB, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000;42:628632.
  • 30
    McLeod HL, Relling MV, Liu Q., et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995; 85:18971902.
  • 31
    Foster AP, Shaw SE, Duley JA, et al. Demonstration of thiopurine methyltransferase activity in the erythrocytes of cats. J Vet Intern Med 2000;14:552554.
  • 32
    White SD, Rosychuk RAW, Outerbridge CA, et al. Thiopurine methyltransferase in red blood cells of dogs, cats, and horses. J Vet Intern Med 2000;14:499502.
  • 33
    Harvey JW. Atlas of Veterinary Hematology. Philadelphia , PA : WB Saunders; 2001: 113123.
  • 34
    MacLean CJ, Morton NE, Elston RC, Yee S. Skewness in commingled distributions. Biometrics 1976;32:695699.
  • 35
    Salavaggione OE, Kidd L., Prondzinski JL, et al. Canine red blood cell thiopurine S-methyltransferase: Companion animal phar-macogenetics. Pharmacogenetics 2002;12:713724.
  • 36
    Kidd L., Trepanier L., Salavagginone E., et al. Azathioprine metabolism in dogs: Implications for drug dosing. Proceedings of the 20th ACVIM Forum, Dallas, TX, 2002.
  • 37
    Lennard L. TPMT in the treatment of Crohn's disease with aza-thioprine. Gut 2002;51:143146.
  • 38
    Sumi S., Marinaki AM, Arenas M., et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002;111:360367.
  • 39
    Fraser JK, Meyers H., Henderson JF, et al. Individual variation in inosine triphosphate accumulation in human erythrocytes. Clin Biochem 1975;8:353364.
  • 40
    Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591602.
  • 41
    Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;50:663672.
  • 42
    Giger U., Werner LL, Millichamp NJ, et al. Sulfadiazine-induced allergy in six Doberman Pinschers. J Am Vet Med Assoc 1985; 186:479484.
  • 43
    Trepanier LA, Cribb AE, Danhof RS, et al. Clinical and immunologic findings in 45 dogs with sulfonamide-associated hypersen-sitivity. Proceedings of the 20th ACVIM Forum, Dallas, TX, 2002.
  • 44
    McLeod HL, Lin JS, Scott EP, et al. Thiopurine methyltrans-ferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:1520.